This is a fixed-combination rapid-dissolving tablet (RDT) containing tadalafil, a PDE5 inhibitor, alongside oxytocin and PT-141 (bremelanotide), a melanocortin receptor agonist. The combination is studied for its role in vascular, melanocortin, and oxytocin signaling and the associated neuroendocrine pathways.

This RDT formulation is used in controlled laboratory workflows and investigative settings examining PDE5, melanocortin, and oxytocin receptor activity, vascular signaling, and behavior-related mechanisms. It is applied in structured research models characterizing compound activity and downstream pathway interactions.

The combination supports analytical studies and cell-based models involving PDE5 inhibition, melanocortin receptor agonism, oxytocin-mediated signaling, arousal-related pathways, and vascular and neuroendocrine cross-talk. It is relevant for pathway characterization and assay development focused on vascular, behavioral, and hormonal mechanisms within controlled study frameworks.

This combination RDT is suited for researchers and investigators studying vascular signaling alongside melanocortin and oxytocin receptor mechanisms within controlled study frameworks.